A phase two study investigating the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective front-line treatment for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.
Myelodysplastic syndrome (MDS) is a type of cancer in which the bone marrow does not make enough healthy blood cells, resulting in abnormal (blast...
By reducing investments in medical research, any short-term savings will prove to be very costly in the long run — and not just financially...
A study investigating the potential of the antifibrotic compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in...
A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it’s among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.
Researchers behind a study at MD Anderson Cancer Center believe they may have found a molecule-based approach to halting 3q26.2’s destructive nature. By manipulating a noncoding microRNA (miRNA) known as miR569 that is part of the amplicon, scientists...
虽然主要的葡萄膜黑色素瘤可以有效地treated with radiation or surgery, patients with metastatic disease — or those at high...
Biotech companies Intrexon and ZIOPHARM Oncology have licensed unique MD Anderson immunotherapy technology, creating an...